CTI Biopharma’s cancer drug fails late-stage trial, shares tumble

CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent.

Leave a Reply

Your email address will not be published. Required fields are marked *